Design, Synthesis, and Biological Evaluation of 2,4-dimorpholinopyrimidine-5-carbonitrile Derivatives As Orally Bioavailable PI3K Inhibitors

Overview

Journal Front Pharmacol

Date 2024 Nov 5

PMID 39498341

Authors

Daowei Huang

Jixia Yang

Qingwei Zhang

Xiaolei Zhou

Yanbo Wang

Zhenhua Shang

Jianqi Li

Baoyin Zhang

Affiliations

Soon will be listed here.

Abstract

Introduction: Phosphoinositide-3-kinase (PI3K) is overexpressed in many tumors and is, thus, an ideal target for cancer treatments. Accordingly, there is an urgent need for the development of PI3K inhibitors with high potency and low toxicity.

Methods: In this study, we designed and synthesized a series of 2,4-dimorpholinopyrimidine-5-carbonitrile derivatives, which were evaluated for their PI3K inhibitory potency.

Results And Discussion: Compound 17p demonstrated comparable PI3Kα inhibitory activity (IC: 31.8 ± 4.1 nM) to the positive control, BKM-120 (IC: 44.6 ± 3.6 nM). In addition, 17p showed significant inhibitory activity against PI3Kδ (IC: 15.4 ± 1.9 nM) and significant isoform selectivity against PI3Kβ, PI3Kγ, and mTOR. Furthermore, 17p exhibited good antiproliferative activities against cancer cell activity and good safety in the Ames and hERG tests while having outstanding liver microsomal stability , with half-lives of 38.5 min in rats and 127.9 min in humans. In addition, in an apoptosis assay, 17p could induce dose-dependent cytotoxicity in the ovarian cancer cell line A2780. In a pharmacokinetic study, 17p was stable ( : 2.03 h) and showed high bioavailability (46.2%). Collectively, these results indicate that 17p could be a promising PI3K agent for cancer treatment.

References

Zhang X, Wang Y, Zhang X, Shen Y, Yang K, Ma Q . Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors. Signal Transduct Target Ther. 2023; 8(1):153. PMC: 10090078. DOI: 10.1038/s41392-023-01359-x. View

De Santis M, Gulluni F, Campa C, Martini M, Hirsch E . Targeting PI3K signaling in cancer: Challenges and advances. Biochim Biophys Acta Rev Cancer. 2019; 1871(2):361-366. DOI: 10.1016/j.bbcan.2019.03.003. View

Markham A . Idelalisib: first global approval. Drugs. 2014; 74(14):1701-7. DOI: 10.1007/s40265-014-0285-6. View

Bai Y, Gotz C, Chincarini G, Zhao Z, Slaney C, Boath J . YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells. Nat Commun. 2023; 14(1):1591. PMC: 10033729. DOI: 10.1038/s41467-023-37161-0. View

Xie W, Chen H, Chen R, Zhao C, Gong X, Zhou X . Intervention effect of Lycium barbarum polysaccharide on lead-induced kidney injury mice and its mechanism: A study based on the PI3K/Akt/mTOR signaling pathway. J Ethnopharmacol. 2023; 319(Pt 2):117197. DOI: 10.1016/j.jep.2023.117197. View

Garces A, Stocks M . Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. J Med Chem. 2018; 62(10):4815-4850. DOI: 10.1021/acs.jmedchem.8b01492. View

Borsari C, Rageot D, DallAsen A, Bohnacker T, Melone A, Sele A . A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. J Med Chem. 2019; 62(18):8609-8630. DOI: 10.1021/acs.jmedchem.9b00972. View

Dugar S, Hollinger F, Mahajan D, Sen S, Kuila B, Arora R . Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines. ACS Med Chem Lett. 2015; 6(12):1190-4. PMC: 4677375. DOI: 10.1021/acsmedchemlett.5b00322. View

Yang Y, Sun X, Luo L, Peng R, Yang R, Cheng Z . Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity. Arch Pharm (Weinheim). 2023; 356(12):e2300403. DOI: 10.1002/ardp.202300403. View

10.

Vanhaesebroeck B, Perry M, Brown J, Andre F, Okkenhaug K . PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021; 20(10):741-769. PMC: 9297732. DOI: 10.1038/s41573-021-00209-1. View

11.

Markham A . Copanlisib: First Global Approval. Drugs. 2017; 77(18):2057-2062. DOI: 10.1007/s40265-017-0838-6. View

12.

Wei T, Lu S, Sun J, Xu Z, Yang X, Wang F . Sanger's Reagent Sensitized Photocleavage of Amide Bond for Constructing Photocages and Regulation of Biological Functions. J Am Chem Soc. 2020; 142(8):3806-3813. DOI: 10.1021/jacs.9b11357. View

13.

Miller M, Pinson J, Zheng Z, Jennings I, Thompson P . Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase. Bioorg Med Chem Lett. 2012; 23(3):802-5. DOI: 10.1016/j.bmcl.2012.11.076. View

14.

Li T, Wang J, Wang X, Yang N, Chen S, Tong L . WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J Pharmacol Exp Ther. 2010; 334(3):830-8. DOI: 10.1124/jpet.110.167940. View

15.

Abdel-Aziz S, Taher E, Lan P, Asaad G, Gomaa H, El-Koussi N . Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives bearing 1,3-thiazole moiety as novel anti-inflammatory EGFR inhibitors with cardiac safety profile. Bioorg Chem. 2021; 111:104890. DOI: 10.1016/j.bioorg.2021.104890. View

16.

Hennessy B, Smith D, Ram P, Lu Y, Mills G . Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4(12):988-1004. DOI: 10.1038/nrd1902. View

17.

Zhang X, Yang L, Liu X, Nie Z, Liu M, Wang T . Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway. Biochim Biophys Acta Mol Cell Res. 2023; 1871(1):119607. DOI: 10.1016/j.bbamcr.2023.119607. View

18.

Nasser A, Eissa I, Oun M, El-Zahabi M, Taghour M, Belal A . Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR and EGFR. Org Biomol Chem. 2020; 18(38):7608-7634. DOI: 10.1039/d0ob01557a. View

19.

Cantley L . The phosphoinositide 3-kinase pathway. Science. 2002; 296(5573):1655-7. DOI: 10.1126/science.296.5573.1655. View

20.

Till K, Abdullah M, Alnassfan T, Janet G, Marks T, Coma S . Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib. Sci Rep. 2023; 13(1):3793. PMC: 9992372. DOI: 10.1038/s41598-023-30148-3. View